

# Cloudy, With A Chance of Regulation: Getting Ahead Of The Storm

Stuart Fedderson, MBA, CPC, CPS Associate Director, Revenue Integrity











### Natural Catastrophe Losses in The United States




As of March, 2019	Number of Events	Fatalities	Estimated Overall Losses (US \$bn)	Estimated Insured Losses (US \$bn)*
Severe Thunderstorm	56	66	18.8	14.1
Winter Storms & Cold Waves	9	26	4.2	3
Flood, Flash Flood	20	49	2.6	1.2
Earthquake & Geophysical	2		0.5	0.4
Tropical Cyclone	5	107	30.4	15.6
Wildfire, Heat Waves, & Drought (ongoing drought condition without loss estimation for the half year)	16	107	25.4	18
Totals	108	355	\$81.9	\$52.3




# Advanced Storm Surge Modeling









### Feeling Overwhelmed?






According The Advisory Boards most recent survey:

The Average 350-bed hospital is losing an average of \$22 million in revenue due to the complexity of regulatory audits, denials, and missing charge capture.

This is lost revenue that could be used to save more lives, treat more patients, and re-invest back into your respective organization for improved patient care.

#### ACHE 2018 Most Pressing Concerns for Healthcare Executives





#### Government Mandates Breakdown

Governmental Mandates (n=355) <sup>1</sup>	All respondents
CMS regulations	70%
Regulatory/legislative uncertainty affecting strategic planning	61%
Cost of demonstrating compliance	59%
State and local regulations/mandates	50%
CMS audits (RAC, MAC, CERT)	46%
Other	n = 17

<sup>1</sup>If number of respondents is fewer than 50, only numbers are provided.


In a recent survey conducted by Ingenious Med looking at how charge capture is conducted and perceived uncovered the following:

Accurate Charge capture is critical for success but is not a frequent agenda item.

Over three-quarters (78%) of respondents characterize charge capture as "essential" to their organization's success. Twenty-one percent characterize it as useful, and 1 percent say it's optional.

Despite this, leadership teams at 40% of organizations talk about charge capture once a month or less. One-third (32%) discuss it weekly, while 18 percent discuss it twice a month, 8 percent discuss it daily, and 2 percent never discuss it

Source <a href="https://www.prnewswire.com/news-releases/78-of-healthcare-execs-say-charge-capture-is-essential-yet-40-discuss-it-once-a-month-or-less-300774051.html">https://www.prnewswire.com/news-releases/78-of-healthcare-execs-say-charge-capture-is-essential-yet-40-discuss-it-once-a-month-or-less-300774051.html</a>





"Revenue Integrity is a proactive approach that focuses on assessing and minimizing risk and making sure you are focusing in on the key areas of importance."


"It's almost like having an [cms] auditor working from inside of your organization."


"Revenue cycle is focused more on integrating multiple transactions, where Revenue Integrity is about taking a step back and trying to prevent problems of the future."

Todd Nelson, Director of Partner Relations HFMA



# Duke's Revenue Integrity Scope





### Advanced External Audit Surge Modeling

A state-of-the-art prevention plan to better mitigate and understand the risks associated with regulatory storm surges.

This involves proactively identifying high risk procedures, performing a **mock CMS audit** on those procedures, followed by remediation of any identified variances.

This puts your organization 10 steps ahead of CMS and other external audit contractors which then leads to revenue preservation and optimization.

### Advanced External Audit Surge Modeling

- 1. Pull Revenue and Usage Report for the past year
- 2. Pivot the top ten High Dollar CPT Codes
- 3. Pivot the top ten High Volume CPT Codes
- 4. Reconcile the identified CPT Codes with National and Local Coverage Determinations

- 5. Research OIG High Risk Areas
- 6. Research Approved RAC Topics
- 7. Research MAC Focus Areas (Palmetto, Noridian, etc.)
- 8. Draft Annual Proactive Audit Plan based upon findings.
- 9.Conduct mock CMS Audits using Six Sigma DMAIC Model and remediate as needed.



# Pull Revenue and Usage Report











# Pivot on top ten High Dollar CPT Codes








# Pivot on Top Ten High Volume Codes








### Reconcile with Local and National Coverage Determinations





### Research OIG Work Plan




Announced or Revised	Agency	Title	Component	Report Number(s)
August 2019	Centers for Medicare & Medicaid Services	Medicare Payments of Positive Airway Pressure Devices for Obstructive Sleep Apnea Without Conducting a Prior Sleep Study	Office of Audit Services	W-00-19-35823
August 2019	Centers for Medicare & Medicaid Services	States' Medicaid Agency Claims for Indian Health Service Expenditures	Office of Audit Services	W-00-19-31538
August 2019	Centers for Medicare & Medicaid Services	Review of the Medicare DRG Window Policy	Office of Evaluation and Inspections	OEI-05-19-00380
August 2019	Centers for Medicare & Medicaid Services	Opioids in Medicaid: Review of Extreme Use and Overprescribing in the Appalachian Region	Office of Evaluation and Inspections	OEI-05-19-00410
August 2019	Centers for Medicare & Medicaid Services	Medicare Market Shares for Diabetic Testing Strips from April to June 2019	Office of Evaluation and Inspections	OEI-04-19-00480 OEI-04-19-00481
August 2019	Centers for Medicare &	Nursing Homes: CMS Oversight of State Survey Agencies	Office of Evaluation and Inspections	OEI-06-19-00460






# Research Approved RAC Topics





### Research MAC Focus Areas





### Draft Annual Proactive Audit Plan

Month	CPT Code(s)	CPT Code Description	LCD/NCD Criteria	Auditor	Audit Complete	Error Rate	Audit Report Distributed
Sep-19	93306	Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography					
Sep-19	G0257	Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility					
Sep-19		Intravitreal injection of a pharmacologic agent (separate procedure)					
Oct-19	11042-11047	Surgical Debridement					
	82542, G6053, G6056, G6042, G6031, G6044	Diagnostic Services					
	90832-90836	Psychiatry and Psychotherapy	LCD L37633				
Nov-19		Under Diagnostic Radiology (Diagnostic					
Dec-19		85025 Under Hematology and Coagulation Proced	NCD 110.4				
Dec-19	MOIDX	MOIDX	MOIDX				
Jan-20		Physical Medicine and Rehabilitation 97112 Therapeutic Procedures	LCD L34427				
Jan-20	97161-97163		LCD 34428				DDM
Feb-20		97140 Manual therapy techniques (eg, mobilization	LCD L34427				PRIVIO
Feb-20		36522 Extracorporeal Photopheresis	NCD 110.4				Engage . Value . Deliver
Mar 20	C1300		NCD 20 20				



### **DMAIC Collaborative Initiative**

The Six Sigma DMAIC (Define, Measure, Analyze, Improve, Control) methodology can be thought of as a roadmap for problem solving and process improvement."

https://www.isixsigma.com/new-to-six-sigma/dmaic/six-sigma-dmaic-roadmap/





### **DMAIC Collaborative Initiative**

#### DEFINE

Define the problem and the ideal in terms of the target to achieve.

### **MEASURE**

Collect relevant data about the process and the problem.

#### **ANALYSE**

Analyse the process to identify the cause-effect relationship between inputs and outputs. Identify the vital few root causes.

Determine the optimum values for key contributing process inputs. Implement solutions to eliminate the root causes.

**IMPROVE** 

#### **CONTROL**

Establish standards and controls to sustain improvements in the long run.





# **DMAIC Alignment Teams**

Service Lines	Revenue Integrity	Revenue Manager	CDM	Coding Integrity	HIM-CS
Children's Health, PT,OT, Women's Health	Jackie	Kenya Bennet	Shirley King	Denise Williams	
Transplant, Surgical Clinics, MSCC, DUH Amb (ENT, Urology, Oral/Dental, Voice, Urodyn, Surgery Clinics)	Hayat	Jared Collins	Miguel Cabral	Ella King	
Perioperative Services, GI Endo/Bronch, DRH	Shirleen	Nieesha Newlin	Shirley King	Kim Londo	
Heart Center Clinics, Cancer Center Clinics	Jan	Robert White	Pat Clarke	Bobette Haley	
Pharmacy, ABMT, Infusion Therapy	Carnetta	Monica Card	Kim Griffin	Kim Londo	
Clinical Lab	Karen	Kari Ryan	Debbie Jacobs	Kim Londo/ Collaboration with others	
Neuro/Psych/DUH Ambulatory (Infect. Dis., Endocrin. Hematology, GYN/Rheum/GET, etc)	Tim (Interim)	Deanna Allen	Kim Griffin	Janet Lewis/Debbie Cooper	
Duke Primary Care	Tim	Mario Vescio	Miguel Cabral	Thomas Beach / Primary Care	
Radiology, Heart Center Labs (Cath/EP)	Denise	Ronda Malnar	Debbie Jacobs	Trina Holloway	
ED/DRAH, Wound Care, Pain Mgmnt	Tanya	Heidi Ballard	Pat Clarke	Kathy Kirk	
Service Line Generalist and Support: Tim (Regulations)					
Service Line Generalist and Support: Valerie (Co	oding)				
Service Line Generalist and Support: Lee (Regula	itions)				



#### Understanding the DMAIC Process

Project assigned to DMAIC Alignment Teams, with each team consisting of a representative from Revenue Integrity, Revenue Management, CDM, and Charge Integrity. Measure Revenue Revenue Revenue Generation Preservation Assurance •••• Through use of the DMAIC 10 Root Cause Task Force Teams: Work through the DMAIC Steps: ■ Transplant, Surgical Clinics, MSCC 1. Define the problem. Process, we achieve Revenue ■ Children's Health, PT, OT, Women's 2. Measure against criteria (audits/trending) Generation, Revenue Cardiac, Cancer Center 3. Perform root cause analysis Preservation and Revenue Periop, GI Endo/Bronch 4. Improve and educate at the source; Assurance.

standarize throughout the system

5. Monitor to ensure integrity and consistency

Duke Primary Care

Pharmacy

■ Neuro/Psych


Lab

RadiologyED/DRAH



# Percutaneous Tranluminal Angioplasty (PTA)

- Percutaneous- via the skin
- Transluminal- involving the passage of an inflatable catheter along the lumen of a blood vessel
- Angioplasty- surgical unblocking of a blood vessel
- Stent- small mesh tube placed inside the blood vessel to keep it open





### PTA DMAIC Project: Define the Problem





#### Analysis of data:

In 2018, Utilizing Advanced External Audit Surge Modeling, the National Coverage Determination (NCD) 20.7 was identified as a high dollar/high risk area that could cause significant revenue leakage if audited by external auditors.



# PTA DMAIC Project: Measure the Problem





■ In 6/2018, the DMAIC PTA Audit Tool was created to **measure** the indications and limitations of coverage based upon CMS' NCD 20.7 guidelines.



# PTA DMAIC Project Audit Criteria





100-3

#### National Coverage Determination (NCD) for Percutaneous Transluminal Angioplasty (PTA) (20.7)

Percutaneous Transluminal Angioplasty (PTA)

Expand All | Collapse All

#### Tracking Information

Manual Section Title Publication Number Manual Section Number

Version Number Effective Date of this Version Implementation Date 3/11/2013

1/1/2013

#### Description Information

#### Benefit Category

Inpatient Hospital Services Physicians' Services

Please Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

#### Item/Service Description

#### A. General

This procedure involves inserting a balloon catheter into a narrow or occluded blood vessel to recanalize and dilate the vessel by inflating the balloon. The objective of percutaneous transluminal angioplasty (PTA) is to improve the blood flow through the diseased segment of a vessel so that vessel patency is increased and embolization is decreased. With the development and use of balloon angioplasty for treatment of atherosclerotic and other vascular stenoses, PTA (with and without the placement of a stent) is a widely used technique for dilating lesions of peripheral, renal, and coronary arteries.

#### Indications and Limitations of Coverage

#### B. Nationally Covered Indications

The PTA is covered when used under the following conditions:

#### 1. Treatment of Atherosclerotic Obstructive Lesions

-In the lower extremities, i.e., the iliac, femoral, and popliteal arteries, or in the upper extremities, i.e., the innominate, subclavian, axillary, and brachial arteries. The upper extremities do not include head or neck vessels.

- -Of a single coronary artery for patients for whom the likely alternative treatment is coronary bypass surgery and who exhibit the following characteristics:
  - · Angina refractory to optimal medical management;
  - · Objective evidence of myocardial ischemia; and
  - · Lesions amenable to angioplasty.



# PTA DMAIC Error Rate Audit



GTR	HB HAR	Admit Date	D/C Dept	ICD-10 Dx Code	PCS Code	PERFORMING_PRVDR_NM	Charge Amount	MRN	Auditor	Audit Date
Medicare	111111111111	8/13/2018	DUH N3200 General Surgery	165.21	037K3DZ		60852.04	PY1127	Jan Bledsoe	9/4/2018

	Score	Possible
		2
6.11	2	2
Subtotal =	2	2
prior bilateral CEA	2	2
Asymptomatic high-grade recurrent right ICA stenosis. 95-99% stenosis at the right ICA.	0	2
yes	2	2
Subtatal -	12	14
- Induduc		27
tme	2	2
yes		4
	Asymptomatic high-grade recurrent right ICA stenosis. 95-99% stenosis at the right ICA.  yes yes yes	Asymptomatic high-grade recurrent right ICA stenosis. 95-99% stenosis at the right ICA.   yes yes yes yes yes 2 yes yes 2 Subtotal = 12



# PTA DMAIC Error Rate Audit




### Root Cause Analysis; Insufficient physician documentation

Indication/Limitations of Coverage (11 accounts reviewed)	Error Rate %	1	2	3	4	5	6	7	8	9	10	11
Treatment of Atherosclerotic Obstructive Lesions	0%	Р	Р	Р	Р	Р	Р	Р	Р	Р	Р	Р
High Risk Candidate for CEA	36%	F	Р	Р	Р	Р	F	Р	F	Р	Р	F
Select one of the following: o Symptomatic carotid artery stenosis ≥ 70%, w/ FDA-approved stenting and FDA-Approved Embolic Protection Device o Symptomatic carotid artery stenosis between 50% and 70%, in a Category B IDE Clinical Trial or in a Post-Approval Study o Asymptomatic carotid artery stenosis ≥ 80%, in a Category B IDE Clinical Trial or in a Post-Approval Study	73%	Р	F	F	F	F	Р	Р	F	F	F	F
Angiography (pre-procedure or at start of procedure)	0%	Р	Р	Р	Р	Р	Р	Р	Р	Р	Р	Р
% of Stenosis recorded prior to procedure	18%	Р	Р	Р	Р	F	Р	Р	F	Р	Р	Р
FDA-Approved or cleared Embolic Protection Device used	18%	Р	Р	Р	Р	Р	F	Р	F	Р	Р	Р
FDA-Approved Embolic Protection Device charged	18%	Р	Р	Р	Р	Р	F	Р	F	Р	Р	Р
FDA-Approved Stent charged	0%	Р	Р	Р	Р	Р	Р	Р	Р	Р	Р	Р
Approved ICD-10 CM Code meets medical necessity	0%	Р	Р	Р	Р	Р	Р	Р	P	Р	Р	Р

Anything other than a 0% in each element resulted in a write-off

### PTA DMAIC Project: Analyze for Root Cause





- A total of 11 accounts(DUH & DRAH, 7 providers) were audited; root causes were identified and prioritized.
  - 78% of the accounts failed to identify patient's symptoms and/or involvement in a Category B IDE Clinical Trial or in a Post-Approval Study
  - 36% of the accounts failed to identify if the patient was a High Risk Candidate for CEA
  - 18% of the accounts failed to provide sufficient documentation for the following:
    - % of stenosis recorded prior to procedure
    - Utilization and charging of a FDA-Approved Embolic Protection Device



# PTA DMAIC Project: Summary



### **Impact**

Bill Area	CPT Code	PB\$ at Risk
ANESTHESIA CHRONIC PAIN - PDC [208220000016]	01925	\$2,247
ANESTHESIA NEURO DIVISION - PDC [208220000018]	01925	\$2,247
ANESTHESIA-GVTU DIVISION - PDC [208220000019]	01916, 01925	\$14,231
Cerebrovascular & Skull Base - PDC [208250000033]	37215, 37216, 61635	\$23,196
CRNA DUKE NORTH - DUH [208230000042]	01916, 01925	\$870
DUKE CARDIOLOGY OF RALEIGH-CPDC [208240000009]	37215	\$5,776
INTERNATIONAL PHY-ANES - PDC [208220000104]	01925	\$4,387
VASCULAR SURGERY - PDC [208220000204]	37215	\$40,622
Grand Total		\$93,576

Department	Inpatient Procedures / ICD- 10-PCS Code	HB\$ at Risk
DRAH CARDIAC CATH LAB [1000303008]	037L3DZ	\$37,326
DUKE NORTH NEURO/VASC IR [1000100092]	037K34Z, 037K3D6, 037L3DZ	\$198,879
DUKE NORTH OR [1000100841]	037K3DZ, 037L3GZ, 037L3DZ, 037J3DZ	\$437,100.23
DUKE NORTH PERIOP [1000100840]		
Grand Total		\$673,305.77

- Specificity Error Rate:
  - **18.09%**
- Denial Rate:
  - 91%



# PTA DMAIC Project: Improve





- From 07/18 to 01/19, the RI Analyst met with Revenue Managers to establish the corrective action.
- On 12/20/18, the RI Analyst spoke with the Medical Director to review the results of the audit.
- In an effort to enhance physician documentation, the Medical Director agreed to share the findings with fellow surgeons and update their EPIC documentation template.
- On 01/15/19, Medical Director confirmed that the template and her fellow surgeons had been updated.



## PTA DMAIC Project: Control and Monitor





- To ensure the action items in the improve phase were well-implemented, RI performed a 30 day post-audit review on 01/28/19.
- 3 accounts were reviewed:
  - 3 were favorable (met ALL criteria)
- Based upon the monitored data, The Medical Director and the PB Revenue Manager will be notified of the post-audit findings, encouraged of favorable outcomes and assisted in identifying measures to prevent unfavorable occurrences.





### **Duke PRMO Mission and Values**

#### PRMO Cycling for Our Patients Engage . Value . Deliver



People:

Experience

Recruitment,

Development

Retention,

Collaboration

Innovation

and Best

Practice

Revenue

Performance

Cycle



# Revenue Cycle Re-framed Podcast











# Final Thoughts

There's no harm in hoping for the best as long as you're prepared for the worst.

- Stephen King



# PREPAREDNESS IS THE ONLY WAY WE CAN COMBAT A NATURAL DISASTER.

QUOTEHD.COM

John Quinlan





# Questions?









# Thank you!

### Stuart.fedderson@duke.edu



